Company intelligence / Profile preview

Eos Biosciences

Los Angeles, California, United States

Ownership: Private
Development stage: Other

Overview

Eos Biosciences was a bio-pharmaceutical company focused on the development of targeted medicines for the treatment of cancer. The company's primary technology platform, Eos-002, was a proprietary HER3-targeted antibody-drug conjugate (ADC) delivery vehicle designed to improve the therapeutic index of potent chemotherapeutic agents. By targeting the HER3 receptor, which is overexpressed in many solid tumors, Eos aimed to deliver high concentrations of drugs directly to cancer cells while minimizing systemic toxicity. The company was acquired by Bionaut Labs in 2021 to integrate its targeting technology into micro-robotic delivery systems.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateNanoparticle
Industry: Biotech

Drug pipeline

1 asset

Eos-001

Preclinical

Beyond the preview

Go deeper on Eos Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eos Biosciences.

Explore the full profile